Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11954930 | 0.83 | ALOX5AP (0.34) | AAK1 | |
| SCHEMBL30007751 | 0.80 | GPBAR1 (0.34) | MAP4K4MINK1TNIKHCRTR1HCRTR2 | |
| SCHEMBL2651520 | 0.80 | GPBAR1 (0.34) | MAP4K4MINK1TNIKHCRTR1HCRTR2 | |
| SCHEMBL24783824 | 0.77 | KDM4E (0.36) | MAP4K4MINK1TNIK | |
| SCHEMBL24140202 | 0.76 | MEN1 (0.34) | AAK1 | |
| SCHEMBL11099450 | 0.76 | AAK1 (0.35) | AAK1 | |
| SCHEMBL646416 | 0.75 | NAPRT (0.42) | MAP4K4MINK1TNIKNAPRT | |
| SCHEMBL30007231 | 0.74 | BCHE (0.40) | — | |
| SCHEMBL25686895 | 0.74 | BCHE (0.40) | — | |
| SCHEMBL30007243 | 0.71 | KMO (0.38) | MAP4K4MINK1TNIKAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725434-B2 | Hydroxy-substituted orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725434-B2 | Hydroxy-substituted orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725434-B2 | Hydroxy-substituted orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160068510-A1 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068510-A1 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068510-A1 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2988748-A1 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014176142-A1 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014176142-A1 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068510-A1 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | MAP4K4 4390/4885MINK1 3464/4885TNIK 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.